- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01678144
Study on Safety and Performance of Medtentia Mitral Valve Repair System in Surgical Repair of Mitral Regurgitation
Evaluation of the Safety and Performance of the Medtentia Mitral Valve Repair System When Used in Adults Undergoing Mitral Valve Repair Surgery
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The purpose of this study is to evaluate the safety and performance of the MAR in patients with mitral regurgitation requiring either isolated mitral valve annuloplasty or mitral valve annuloplasty concomitantly with any of the following, either individually or in combination:
- Tricuspid valve repair
- Coronary artery bypass grafting (CABG)
- Valve resection and chordae repair
- Correction of atrial septal defect
- Correction of patent foramen ovale
- Ablation therapy for atrial defibrillation
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Helsinki, Finland, 00029
- Helsinki University Hospital, Cardiovascular and Thorax Surgery Clinic
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria:
Eligible patients must meet all the following inclusion criteria:
- Signed Informed Consent Form.
- Male or female aged ≥18 to ≤ 85 years on the day of screening. Females of childbearing potential (not surgically sterilized or more than one year post-menopausal) must have a negative pregnancy test (serum beta-human chorionic gonadotropin (beta-hCG) or urine) within 24 hours prior to mitral valve surgery.
Patient must meet one of the following indications for mitral repair surgery according to the European Society of Cardiology (ESC) and the American Heart Association (AHA) guidelines, and must have consented to have such surgery before undergoing the informed consent process for this study.
- Symptomatic patient with chronic severe primary mitral regurgitation (MR), left ventricle ejection fraction (LVEF) > 30% and left ventricle end systolic diameter (LVESD) < 55 mm or
Asymptomatic patient with chronic severe primary MR who either:
- Has LV dysfunction (LVEF ≤ 60 % and/or LVESD ≥ 40 mm or
- Has a preserved LV function (LVEF> 60% and LVESD < 40 mm) together with a likelihood of a successful and durable repair of > 95 % and an expected mortality rate of < 1% or
- Has a flail leaflet and LVESD ≥ 40 mm together with a high likelihood of durable repair and a low surgical risk or
- Has a new onset of atrial fibrillation or pulmonary hypertension (systolic pulmonary pressure > 50 mm Hg at rest) or
- Asymptomatic patient with chronic moderate or severe primary MR who is to undergo cardiac surgery for another indication when the mitral valve (MV) repair can be performed concomitantly
- Patient with chronic severe or moderate secondary MR and an LVEF > 30 % who is undergoing CABG concomitantly
- Patient must have a life expectancy of more than 24 months at the time of screening, assuming they undergo mitral valve annuloplasty.
- Patient must have a mitral valve diameter corresponding to MAR size 26 - 40 and leaflet thickness (smallest helix height - largest helix height) for which an appropriate MAR ring is available.
- Patient must be able and willing to attend all scheduled visits and comply with all study procedures.
Exclusion criteria:
Eligible patients must not meet any of the following exclusion criteria:
- Have had previous cardiac surgery, including but not limited to any of the following: minimally invasive surgery, mitral valve surgery or valvuloplasty, implantation of a prosthetic heart valve or cardiac defibrillator.
- Have ejection fraction below 30%.
- Plan to have any concomitant cardiac surgery or procedure other than CABG, tricuspid valve repair, correction of atrial septal defect, closure of auricular appendage, correction of patent foramen ovale and/or ablation therapy for correction of atrial fibrillation performed with the mitral valve repair, which may also include leaflet resection and chordae replacement.
- Have any structural hindrance or heart abnormality that would make use of the MAR technically infeasible, such as a mitral valve of an unusual size or leaflet thickness for which a suitable MAR is not available, or an obstruction or other abnormality that blocks positioning of the MAR. (Final determination to be made during surgery).
- Show evidence of having had an acute myocardial infarction (MI) within the 30 days preceding the mitral valve repair surgery.
- Have a history of stroke within the preceding 12 months or have had any stroke that is not completely clinically resolved and/or significant carotid artery disease (subjects with carotid stenosis ≥50% and/or ulceration).
- Have recent or evolving bacterial endocarditis or be undergoing antibiotic therapy.
- Have restricted mobility of the mitral apparatus that results in a valvular area less than 3.0 cm2.
- Be in need of annular decalcification.
- Have any comorbidities or conditions that would be a contraindication to open heart surgery or that would place the patient at an unacceptable surgical risk, such as: severe chronic obstructive pulmonary disease (COPD); hepatic failure; immunosuppressive abnormalities or other immunological deficiencies including being immunocompromised or having an autoimmune disease; chronic renal failure requiring dialysis; hematological abnormalities including a history of bleeding diathesis or coagulopathy; being unable to follow the locally recommended anticoagulant regimen; an intolerance or hypersensitivity to anesthetics; cancer that requires further radiation, chemotherapy or surgical treatment.
- Have a contraindication to trans-esophageal echocardiography (TEE)/ Doppler.
- Have any recent psychiatric disorder, including drug or alcohol abuse, that in the Investigator's opinion could impair the patient's compliance with study procedures.
- Be currently or have in the preceding 30 days participated in any other study involving an investigational drug or device.
- Be an employee of the investigational site directly affiliated with this study, the sponsor or the clinical research organization or have an immediate family member who is.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Medtentia Annuloplasty Ring (MAR)
All eligible patients underwent surgical mitral valve repair using annuloplasty device - Medtentia Annuloplasty Ring (MAR)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety: All-cause Mortality Occurring in the Time From Surgery Through Hospital Discharge.
Time Frame: Time from surgery through hospital discharge, up to 7 days.
|
Time from surgery through hospital discharge, up to 7 days.
|
|
Performance: Percentage of Participants With Improvement by at Least 2 Mitral Regurgitation Classes From Baseline (SC) to Three Months (V03) as Measured by Trans-thoracic Echocardiography (TTE).
Time Frame: Time from baseline through V03 (3 months)
|
Success will be defined as an improvement in at least 2 degrees in mitral regurgitation (MR) class as described in the ACC/AHA Guidelines for the Management of Patients with Valvular Heart Disease (Bonow, et al., 2008).
|
Time from baseline through V03 (3 months)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety: 30-day Mortality and Mortality at 3 Months, 6 Months, 1 Year, 1.5 Years and 2 Years.
Time Frame: 30 days, 3 months, 6 months, 1 year, 1.5 years and 2 years after surgery
|
Mortality rates determined both for all-cause mortality and for related deaths only.
For the former, the causality status will be determined by the Investigator, and all deaths that are clearly unrelated to the device, the surgery or the underlying medical condition will be excluded from the analysis.
|
30 days, 3 months, 6 months, 1 year, 1.5 years and 2 years after surgery
|
Safety: The Occurrence, Frequency and Timing of Treatment-emergent Major Adverse Cardiac Events (MACEs).
Time Frame: From surgery to end of study (2 years)
|
MACE is defined as stroke and clinically significant myocardial infarction (MI), from surgery to end of study.
|
From surgery to end of study (2 years)
|
Safety: The Occurrence, Nature and Frequency of Treatment-emergent Adverse Events (AEs), in Particular Severe Serious Adverse Device Effects (SADEs).
Time Frame: From surgery to end of study (2 years).
|
All the adverse events reported were non-device related.
|
From surgery to end of study (2 years).
|
Safety: The Occurrence, Nature and Frequency of Device Deficiencies and Adverse Device Effects (ADEs).
Time Frame: From surgery to end of study (2 years).
|
From surgery to end of study (2 years).
|
|
Safety: The Occurrence, Frequency and Nature of Abnormalities in the Period From Surgery Through Follow-up (Detailed List in Description Field).
Time Frame: From surgery to end of study (2 years).
|
The occurrence, frequency and nature of abnormalities in any of the following:
|
From surgery to end of study (2 years).
|
Performance: Mitral Regurgitation (MR) as Seen in Trans-esophageal Echocardiography (TEE) Performed During Surgery Before and After Annuloplasty.
Time Frame: Day of surgery visit (V01).
|
Success will be defined as no or only residual mitral regurgitation (MR).
|
Day of surgery visit (V01).
|
Performance: Percentage of Participants With Improvement by at Least 2 Mitral Regurgitation Classes at Each Follow-up Visit (V04-V06) of the Improvement in MR From Screening, as Measured by Trans-thoracic Echocardiography (TTE).
Time Frame: V06 (24 months)
|
Measurement analysis at 24 months after successful MAR implantation.
|
V06 (24 months)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Exploratory: Change in the Mitral Regurgitation (MR) Parameters, as Measured Using TTE.
Time Frame: From screening to end of study (up to 2 years)
|
Change from screening at each follow-up visit in the following MR parameters, as measured using TTE:
|
From screening to end of study (up to 2 years)
|
Exploratory: Duration of the Key Stages of the Annuloplasty Procedure.
Time Frame: Day of surgery visit (V01)
|
Duration of the following key stages of the annuloplasty procedure:
|
Day of surgery visit (V01)
|
Exploratory: Changes From Screening in NYHA Classification at All Follow-up Visits Except Discharge.
Time Frame: At screening and at each follow-up visit (except for discharge visit, up to 2 years).
|
At screening and at each follow-up visit (except for discharge visit, up to 2 years).
|
|
Exploratory: Thickness of the Anterior Leaflet Segment A2 and the Posterior Scallop P2 of the Mitral Valve (MV) Leaflets, as Measured With the Dedicated Medtentia Leaflet Measurement Tool.
Time Frame: Day of surgery visit (V01)
|
Day of surgery visit (V01)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Kalervo Werkkala, M.D., Prof., Helsinki University Central Hospital
Publications and helpful links
General Publications
- Konerding MA, Simpanen J, Ihlberg L, Aittomaki J, Werkkala K, Delventhal V, Ackermann M. Comparison of the novel Medtentia double helix mitral annuloplasty system with the Carpentier-Edwards Physio annuloplasty ring: morphological and functional long-term outcome in a mitral valve insufficiency sheep model. J Cardiothorac Surg. 2013 Apr 8;8:70. doi: 10.1186/1749-8090-8-70.
- Jensen H, Simpanen J, Smerup M, Bjerre M, Bramsen M, Werkkala K, Vainikka T, Hasenkam JM, Wierup P. Medtentia double helix mitral annuloplasty system evaluated in a porcine experimental model. Innovations (Phila). 2010 Mar;5(2):114-7. doi: 10.1097/IMI.0b013e3181d84316.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2010-040
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mitral Regurgitation
-
Abbott Medical DevicesCompletedFunctional Mitral Regurgitation | Degenerrative Mitral RegurgitationRussian Federation
-
Ancora Heart, Inc.CompletedMitral Regurgitation | Mitral Valve Regurgitation | Functional Mitral RegurgitationAustria, Lithuania, Germany
-
Heinrich-Heine University, DuesseldorfCompletedMitral Regurgitation | Functional Mitral Regurgitation | Degenerative Mitral Valve RegurgitationGermany
-
Abbott Medical DevicesCompletedMitral Valve Regurgitation | Mitral Valve Incompetence | Mitral Insufficiency | Functional Mitral Regurgitation | Mitral Stenosis With InsufficiencyJapan
-
Mitre Medical Corp.BSWRI Cardiac Imaging Core Lab (CICL)Not yet recruitingIschemic Mitral Regurgitation | Functional Mitral RegurgitationUnited States
-
Hospital Clinic of BarcelonaAbbottUnknownMITRAL REGURGITATIONSpain
-
Boston Scientific CorporationActive, not recruitingCardiovascular Diseases | Mitral Regurgitation Functional | Mitral Valve DiseaseUnited States, Australia
-
Edwards LifesciencesRecruitingMitral Regurgitation | Mitral Insufficiency | Functional Mitral Regurgitation | Degenerative Mitral Valve DiseaseUnited States, Canada, Switzerland, Germany
-
Abbott Medical DevicesActive, not recruitingHeart Failure | Mitral Regurgitation | Mitral Valve Regurgitation | Treatment of Functional Mitral Regurgitation in Symptomatic Heart Failure SubjectsUnited States, Canada
-
Mardil MedicalRecruitingFunctional Mitral RegurgitationCanada, Hungary, France, Germany, Netherlands, Panama, Poland
Clinical Trials on Mitral valve repair using the Medtentia Annuloplasty Ring (MAR)
-
Medtentia International Ltd OyCompletedMitral Regurgitation | Mitral InsufficiencyFinland
-
Meshalkin Research Institute of Pathology of CirculationCompletedMitral Regurgitation
-
Southern Illinois UniversityWithdrawnMyocardial Infarction | Mitral RegurgitationUnited States
-
Icahn School of Medicine at Mount SinaiNational Heart, Lung, and Blood Institute (NHLBI); Canadian Institutes of Health... and other collaboratorsCompletedCoronary Artery Disease | Mitral Valve InsufficiencyUnited States, Canada
-
University of Maryland, BaltimoreEdwards LifesciencesCompletedCardiac Surgery | Tricuspid Valve RegurgitationUnited States
-
Abbott Medical DevicesCompleted
-
Abbott Medical DevicesCompletedMitral Regurgitation | Mitral Valve Insufficiency | Mitral Valve Regurgitation | Mitral Valve Incompetence | Mitral InsufficiencyUnited States
-
Medtronic Bakken Research CenterCompletedTricuspid Valve InsufficiencyFrance, Israel, Germany
-
Abbott Medical DevicesCompletedMitral Regurgitation | Mitral Valve Insufficiency | Mitral Valve Regurgitation | Mitral Valve Incompetence | Mitral InsufficiencyUnited States
-
LMU KlinikumUnknown